<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-131137" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chronic Lymphocytic Leukemia With Variant Genetics</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Montague</surname>
            <given-names>Andrea M.</given-names>
          </name>
          <aff>McLaren Macomb - Michigan State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pathak</surname>
            <given-names>Surabhi</given-names>
          </name>
          <aff>Kings Daughters Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrea Montague declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Surabhi Pathak declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-131137.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Chronic lymphocytic leukemia (CLL) is the most common type of leukemia, accounting for 22 to 30% of cases in the Western world. It is characterized as a mature B-cell malignancy associated with the clonal proliferation of B-cells. The etiology and pathogenesis of CLL involve a multi-step pathway that leads to a clonal expansion and proliferation of abnormal or malignant mature B lymphocytes. This clonal expansion of malignant B cells extends to the bone marrow, blood, and lymph nodes. This activity reviews the role of variable genetic alterations found in chronic lymphocytic leukemia in terms of prognosis. This activity describes the role genetic variants have in the evaluation and treatment of CLL and highlights the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of chronic lymphocytic leukemia.</p></list-item><list-item><p>Summarize the most common genetic variants associated with chronic lymphocytic leukemia.</p></list-item><list-item><p>Explain the screening indications for chronic lymphocytic leukemia.</p></list-item><list-item><p>Outline the management strategies for patients with chronic lymphocytic leukemia with genetic variants.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131137&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131137">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-131137.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western world.<xref ref-type="bibr" rid="article-131137.r1">[1]</xref><xref ref-type="bibr" rid="article-131137.r2">[2]</xref><xref ref-type="bibr" rid="article-131137.r3">[3]</xref>&#x000a0;It is characterized as a mature B-cell malignancy associated with B-cell clonal proliferation.&#x000a0;The terms CLL and small lymphocytic leukemia (SLL) are used interchangeably. However, the former describes when the patient presents with peripheral blood involvement with greater than 5000 monoclonal B-cells, while the latter describes the lymphoproliferative process, which is limited to the lymph nodes.</p>
        <p>The technological advances in the last decades have made significant strides in understanding the variant genetics involved in CLL. This article will provide a brief overview of CLL and hone in on the different genetic components of the disease and how they relate clinically to disease management.</p>
      </sec>
      <sec id="article-131137.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology and pathogenesis of&#x000a0;chronic lymphocytic leukemia involve a multi-step pathway that leads to a clonal expansion and proliferation of abnormal or malignant mature B lymphocytes. This clonal expansion of malignant B cells extends to the bone marrow, blood, and lymph nodes. Multiple influencing factors can lead to this clonal expansion, including antigenic triggers, cytogenetic abnormalities, and molecular abnormalities such as dysregulated mRNAs and B-cell receptor mutations.<xref ref-type="bibr" rid="article-131137.r4">[4]</xref><xref ref-type="bibr" rid="article-131137.r5">[5]</xref></p>
        <p>Inherited genetic abnormalities and environmental factors play a role in the pathogenesis of CLL.<xref ref-type="bibr" rid="article-131137.r6">[6]</xref>&#x000a0;The incidence of CLL is higher in the western hemisphere compared to Asia and Africa.<xref ref-type="bibr" rid="article-131137.r7">[7]</xref>&#x000a0;The genetic component of CLL is significant, as shown by an 8.5-fold increased risk of CLL for relatives.<xref ref-type="bibr" rid="article-131137.r8">[8]</xref><xref ref-type="bibr" rid="article-131137.r9">[9]</xref>&#x000a0;There is a higher frequency in monozygotic than in dizygotic twins.<xref ref-type="bibr" rid="article-131137.r10">[10]</xref><xref ref-type="bibr" rid="article-131137.r5">[5]</xref>&#x000a0;</p>
        <p>Family members of patients with CLL also have a high likelihood of developing monoclonal B cell lymphocytosis. Epigenetics has been shown to play a role in CLL, for example, histone modifications, such as those associated with active enhancer and promoter elements, and regions of the genome that were actively transcribed. Over-expression of transcription factor binding has also been found in single nucleotide polymorphisms (SNP), which carry an increased risk of CLL.<xref ref-type="bibr" rid="article-131137.r5">[5]</xref>&#x000a0;SNPs are implicated in 41 loci which shows the familial predisposition.</p>
        <p>Environmental factors associated with CLL include exposure to Agent Orange and insecticides. The U.S. Department of Veteran Affairs allows veterans access to benefits if they were exposed to Agent Orange while serving in the military.<xref ref-type="bibr" rid="article-131137.r11">[11]</xref>&#x000a0;Evidence has also shown that insecticides might be a risk factor for CLL. There is limited evidence that viral infections and ionizing radiation increase CLL risk. Other environmental exposures proposed as risk factors, such as blood transfusions, diet, or other lifestyle factors, have not been supported by current evidence.<xref ref-type="bibr" rid="article-131137.r9">[9]</xref></p>
      </sec>
      <sec id="article-131137.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Like many diseases, the incidence of chronic lymphocytic leukemia is significantly impacted by geographical region, gender, race, and age. Globally, CLL is estimated to comprise 191,000 cases and 61,000 deaths.<xref ref-type="bibr" rid="article-131137.r12">[12]</xref>&#x000a0;Geographically, CLL varies significantly mainly between Western and Eastern countries, with incidence rates among Japan and China occurring at around 10% of Western countries.<xref ref-type="bibr" rid="article-131137.r13">[13]</xref><xref ref-type="bibr" rid="article-131137.r14">[14]</xref>&#x000a0;</p>
        <p>More specifically, the incidence in Asia compared to Europe and the United States is 0.01% and 0.06%, respectively.&#x000a0;Further global differences are also seen, with CLL incidence being higher in African countries than in Asian countries but not in their U.S. or European counterparts.<xref ref-type="bibr" rid="article-131137.r15">[15]</xref><xref ref-type="bibr" rid="article-131137.r16">[16]</xref></p>
        <p>In the Western world, CLL is considered the most common type of leukemia, with the United States alone accounting for roughly 25 to 35% of all leukemia cases.<xref ref-type="bibr" rid="article-131137.r1">[1]</xref><xref ref-type="bibr" rid="article-131137.r2">[2]</xref><xref ref-type="bibr" rid="article-131137.r3">[3]</xref>&#x000a0;U.S data on CLL shows approximately 20,160 newly diagnosed patients annually, with 12,360 and 7,530 of those cases being males and females, respectively. As seen from U.S case distributions in gender, CLL has a significant predilection for males. Specifically, data has shown an approximate male-to-female ratio of 1.2:1 to 1.7:1 with an annual incidence rate of 6.75 and 3.65 cases per 100,000 population in males and females, respectively.<xref ref-type="bibr" rid="article-131137.r3">[3]</xref><xref ref-type="bibr" rid="article-131137.r7">[7]</xref>&#x000a0;</p>
        <p>This male predilection is further supported, with European male-to-female annual incidence rates being 5.87 and 4.01 cases per 100,000 population, respectively.<xref ref-type="bibr" rid="article-131137.r17">[17]</xref></p>
        <p>In addition to gender, CLL also has a predilection for older individuals, with the median age at diagnosis being around 70 years old.<xref ref-type="bibr" rid="article-131137.r18">[18]</xref>&#x000a0;Lastly, CLL differs by race, with the highest incidence among White individuals. In contrast, the incidence decreases in Hispanic and African Americans and is the least in the Asian population.<xref ref-type="bibr" rid="article-131137.r7">[7]</xref><xref ref-type="bibr" rid="article-131137.r19">[19]</xref></p>
      </sec>
      <sec id="article-131137.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Chronic lymphocytic leukemia is a neoplasm of mature B cells almost always preceded by monoclonal B cell lymphocytosis (MBL) which refers to an absolute increase in peripheral blood lymphocytosis less than 5000/microL without any disease manifestations. Pathogenesis of the disease is complex and consists of multiple factors&#x000a0;leading to the clonal expansion of CD5 mature B cells in the peripheral blood, bone marrow, and lymph nodes.</p>
        <p>As MBL worsens,&#x000a0;clinical manifestations relating to the abnormal B cell accumulation and subsequent lack of function become apparent. For instance, decreased functional B cells from MBL hinder the body&#x02019;s ability to generate immunoglobulins, resulting in hypogammaglobulinemia and ultimately leading to an impaired immune system&#x000a0;which is often observed as the disease progresses. The abnormal clonal B cells fail to undergo apoptosis and can continue to proliferate in the lymph nodes resulting in lymphadenopathy, a common manifestation&#x000a0;of the disease.</p>
        <p>Furthermore, in the disease process, neoplastic B cell precursors infiltrate the bone marrow leading to impaired hematopoiesis and peripheral blood cytopenia. Infiltration into the spleen leading to splenomegaly is also observed, resulting in increased sequestration of platelets and red blood cells, which may worsen cytopenia.<xref ref-type="bibr" rid="article-131137.r20">[20]</xref></p>
        <p>At the molecular level, the pathogenesis of&#x000a0; CLL&#x000a0;is driven by impaired cell apoptosis and increased cell proliferation secondary to genetic abnormalities and aberrant cellular signaling. Over the last decade, significant technological&#x000a0;developments in the field of molecular biology have advanced the knowledge of the pathogenesis of CLL. With&#x000a0;the advent of FISH (fluorescent in-situ hybridization) technology, it has been found that around 80% of CLL tumors have at least one of four common chromosomal abnormalities. These cytogenetic abnormalities include del(13q14), Trisomy 12, del(11q22-23), and del(17p12), all of which&#x000a0;are restricted to B cells.&#x000a0;</p>
        <p>The most common chromosomal abnormality, del(13q14), is observed in approximately 50 to 60% of CLL tumors and pertains to miR15A and miR16A, microRNA deleted regions.<xref ref-type="bibr" rid="article-131137.r21">[21]</xref>&#x000a0;These microRNA regions, discussed in more detail later on, regulate the expression of proteins needed for cell apoptosis and, consequently, the normal cell cycle. Therefore, without these microRNA regions, cells cannot appropriately react to stress signals, thereby promoting&#x000a0;apoptosis and contributing to the disease process. Additionally, miR16A and miR15A, both found in CLL cells with 13q deletion, upregulates the B cell leukemia/lymphoma (BCL2) gene in CD5+ cells leading to activation of the BCL-2 proto-oncogene aberrant signaling pathway, contributing to the disease process.<xref ref-type="bibr" rid="article-131137.r22">[22]</xref><xref ref-type="bibr" rid="article-131137.r21">[21]</xref></p>
        <p>The second most common chromosomal abnormality, Trisomy 12, is found in approximately 10 to 20% of CLL tumors and is involved in the upregulation of the gene RUNX3.<xref ref-type="bibr" rid="article-131137.r23">[23]</xref>&#x000a0;Currently, the involvement of the RUNX3 gene and the overall impact of Trisomy 12 on CLL remains unclear and is a topic of further research.<xref ref-type="bibr" rid="article-131137.r23">[23]</xref>&#x000a0;Del(11q22-23) has also been found in approximately 10 to 20% of CLL tumors.<xref ref-type="bibr" rid="article-131137.r24">[24]</xref>&#x000a0;This deleted region has the ataxia-telangiectasia (ATM) gene, which is responsible for detecting damaged DNA, which plays a crucial function in the normal cell cycle and, ultimately, cell apoptosis.<xref ref-type="bibr" rid="article-131137.r24">[24]</xref>&#x000a0;</p>
        <p>Understanding this cytogenetic abnormality plays an important role in treatment. CLL cells without or with an abnormal ATM gene function cannot correctly respond to DNA damage induced by chemotherapy and ultimately fail to undergo apoptosis. Del(17p12) is detected in approximately 4-10% of CLL tumors. Del(17p12) leads to the loss of the TP53 gene, which plays a crucial role in cell apoptosis and DNA damage repair. The presence of either Del(17p12) or TP53 mutations has treatment implications; for example, chemotherapeutic agents that work by inducing DNA damage are ineffective in the presence of these mutations.<xref ref-type="bibr" rid="article-131137.r25">[25]</xref><xref ref-type="bibr" rid="article-131137.r26">[26]</xref></p>
        <p>In addition to genetic abnormalities,&#x000a0;certain gene mutations&#x000a0;are&#x000a0;vital to CLL pathogenesis, and multiple subpopulations of evolving malignant cells have been identified.<xref ref-type="bibr" rid="article-131137.r27">[27]</xref><xref ref-type="bibr" rid="article-131137.r28">[28]</xref>&#x000a0;These&#x000a0;alterations affect&#x000a0;intracellular or microenvironment-dependent signaling pathways. Genes involving intracellular signaling pathways include those affecting DNA damage (TP53, ATM, POT1), chromatin modifiers (ASXL1, SETD2, HIST1H1B, HIST1HIE, BAZ2A, ZMYM3, SYNE1, CHD2, ARID1, KMT2D), RNA splicing and metabolism (XPO1, MED12, SF3B1, CNOT3, U1, FUBP1, DDX3X, RPS15, ZNF292). Genes involving microenvironment-dependent signaling include the MAPK-ERK pathway (PTPN11, MAP2K1, KRAS, BRAF, NRAS), Notch signaling (FBXW7, NOTCH1), NF-kB signaling (EGR2, TRAF2, TRAFR3, NFKB2, NRKBIE, BIRC3, NKAP), and B cell receptor (BCR) and Toll-like receptor signaling (IRF4, BCOR, TLR2, KLHL6, IRAK1, PAX5, MYD88).<xref ref-type="bibr" rid="article-131137.r29">[29]</xref><xref ref-type="bibr" rid="article-131137.r30">[30]</xref><xref ref-type="bibr" rid="article-131137.r27">[27]</xref><xref ref-type="bibr" rid="article-131137.r31">[31]</xref></p>
        <p>Of the many somatic gene mutations described, four alterations, NOTCH1, ATM, SF3B1, and TP53 mutations, are detected in over 5% of patients. Notch proteins control the development of hematopoietic cells by working as transmembrane receptors for the cell. Mutations in the coding and non-coding regions of these NOTCH1 proto-oncogenes can lead to worsening disease through splicing events and an overall increase&#x000a0;in their activity.<xref ref-type="bibr" rid="article-131137.r32">[32]</xref>&#x000a0;ATM, as mentioned earlier, is a gene responsible for detecting damaged DNA and inducing cell apoptosis.<xref ref-type="bibr" rid="article-131137.r24">[24]</xref>&#x000a0;</p>
        <p>SF3B1 is the gene responsible for nuclear ribonucleoproteins that create spliceosomes needed for messenger RNA splicing, ultimately affecting the cell cycle.<xref ref-type="bibr" rid="article-131137.r30">[30]</xref><xref ref-type="bibr" rid="article-131137.r33">[33]</xref><xref ref-type="bibr" rid="article-131137.r34">[34]</xref>&#x000a0;TP53, as mentioned earlier, is crucial for responding to DNA damage and inducing cell apoptosis.<xref ref-type="bibr" rid="article-131137.r25">[25]</xref><xref ref-type="bibr" rid="article-131137.r26">[26]</xref></p>
        <p>Another genetic abnormality significant&#x000a0;in the pathogenesis of&#x000a0;CLL includes aberrant expression of microRNA (miRNA), which are small non-coding RNAs that work at the post-transcriptional level. Studies involving miRNA expression in CLL have found direct associations with disease prognosis. For instance, a study of 56 CLL patients found that miR21 and miR155 were overexpressed in nearly all of the analyzed samples.<xref ref-type="bibr" rid="article-131137.r35">[35]</xref>&#x000a0;</p>
        <p>Further illustrating this involvement, a more extensive study found significantly elevated plasma miR155 levels in the study subjects with CLL compared to the standard control sample. This same study also found that miR155 was associated with higher mortality and refractory disease burden.<xref ref-type="bibr" rid="article-131137.r36">[36]</xref>&#x000a0;MicroRNA expression is controlled through epigenetic modifications involving enzymes and tumor suppressor genes, such as histone deacetylase activity and TP53, respectively.<xref ref-type="bibr" rid="article-131137.r37">[37]</xref><xref ref-type="bibr" rid="article-131137.r38">[38]</xref></p>
        <p>Histone deacetylase activity downregulates the expression of miR29b, miR16, and miR15a.<xref ref-type="bibr" rid="article-131137.r37">[37]</xref>&#x000a0;While TP53 directly activates miRNA clusters at the 11q location, upregulating miR34b and miR-34c.<xref ref-type="bibr" rid="article-131137.r38">[38]</xref>&#x000a0;Another important miRNA is miR150,&#x000a0;which in low levels has been associated with high expression levels of FOXP1 and GAB1, both genes involved in BCR signaling in CLL.<xref ref-type="bibr" rid="article-131137.r39">[39]</xref></p>
        <p>Outside of the specific gene mutations in CLL, aberrant signaling pathways&#x000a0;also play a crucial role in the pathobiology of CLL. The three main pathways implicated include antigen-independent BCR signaling, BCL2 proto-oncogene upregulation, and impaired DNA damage response, with the latter two discussed earlier. The antigen-independent BCR signaling pathway directly affects cell survival, growth, differentiation, and cellular adhesion or migration through antigen-independent or antigen-dependent autonomous signaling of CLL cells. As mentioned above, it is affected by low levels of miR150 and high FOXP1 and GAB1 expression.<xref ref-type="bibr" rid="article-131137.r39">[39]</xref>&#x000a0;</p>
        <p>BCR activation leads to the upregulation of kinases PI3K, SYN, BTK, and LYN,&#x000a0;which&#x000a0;leads to cytoplasmic domain integrin activation and&#x000a0;conformational changes leading to more ligand binding to integrin&#x02019;s extracellular activity, ultimately affecting cell proliferation, migration, differentiation, and survival.<xref ref-type="bibr" rid="article-131137.r40">[40]</xref>&#x000a0;</p>
        <p>Lastly, the antigen-independent BCR signaling pathway is also affected by somatic mutations of immunoglobulin heavy chain variable region (IGHV) genes. Mutated IGHV has weaker BCR signaling through narrower antigen specificity, resulting in higher mutation burden and lower driver mutation frequency. Because of this, mutated IGHV CLL cells have a slower proliferation making the disease process more benign and less clinically aggressive. Contrarily, unmutated IGHV CLL cells have sustained BCR signaling by binding to multiple epitopes resulting in lower mutation burden and higher driver mutation frequency. Ultimately this process leads to quicker clonal expansion and more clinically aggressive disease.<xref ref-type="bibr" rid="article-131137.r29">[29]</xref><xref ref-type="bibr" rid="article-131137.r30">[30]</xref><xref ref-type="bibr" rid="article-131137.r41">[41]</xref></p>
      </sec>
      <sec id="article-131137.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The lymph node architecture is effaced by&#x000a0;small mature lymphocytes&#x000a0;with condensed nuclear chromatin. Pseudofollicles have a pale nodular appearance due to the proliferation of large lymphocytes having open nuclear chromatin and more abundant cytoplasm.</p>
        <p>Chronic&#x000a0;lymphocytic leukemia is a low-grade B-cell malignancy and is often characterized by a low proliferation index except for pseudofollicles, which may show increased Ki-67 expression. The expression of CD20, CD5, and CD23 by the neoplastic cells either by flow cytometry or immunohistochemistry is&#x000a0;diagnostic of CLL. Additional findings include smudge cells found as cellular debris and commonly associated with the disease.<xref ref-type="bibr" rid="article-131137.r42">[42]</xref></p>
      </sec>
      <sec id="article-131137.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Chronic lymphocytic leukemia is often an incidental diagnosis in an asymptomatic patient found to have peripheral blood lymphocytosis on complete blood picture evaluation.&#x000a0;However, approximately 5 to 10% of patients present with one or more &#x0201c;B&#x0201d; symptoms, including Fevers of &#x0003e;100.5 F (38 C) for two or more weeks without evidence of infection, night sweats without evidence of injections, extreme fatigue, or unintentional weight loss of &#x02265;10 percent of body weight in the last six months.<xref ref-type="bibr" rid="article-131137.r42">[42]</xref></p>
        <p>The physical examination can reveal lymphadenopathy in 50 to 90% of patients.<xref ref-type="bibr" rid="article-131137.r43">[43]</xref><xref ref-type="bibr" rid="article-131137.r44">[44]</xref>&#x000a0;Lymphadenopathy commonly affects cervical, supraclavicular, and axillary&#x000a0;lymph node regions&#x000a0;with&#x000a0;enlarged lymph nodes that are round, non-tender, firm, and mobile. Organomegaly can occur with splenomegaly and hepatomegaly identified in 25 to 55% and 15 to 25% of patients, respectively.<xref ref-type="bibr" rid="article-131137.r43">[43]</xref><xref ref-type="bibr" rid="article-131137.r44">[44]</xref>&#x000a0;</p>
        <p>Cutaneous&#x000a0;involvement, which is the most common extra lymphoid&#x000a0;presentation of the disease manifesting as&#x000a0;presenting as papules, blisters, ulcers, macules, and nodules, is rare, occurring in only 5% of the cases.<xref ref-type="bibr" rid="article-131137.r45">[45]</xref><xref ref-type="bibr" rid="article-131137.r46">[46]</xref>&#x000a0;Skin biopsy can differentiate it from Richter transformation.&#x000a0;Uncommonly, hyperleukocytosis&#x000a0;can lead to cerebrovascular accidents such as strokes and transient ischemic attacks secondary to increased blood hyperviscosity.<xref ref-type="bibr" rid="article-131137.r47">[47]</xref></p>
      </sec>
      <sec id="article-131137.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Chronic lymphocytic leukemia should be suspected in the presence of the above-described clinical findings or laboratory findings such as lymphocytosis, cytopenias, or immunoglobulin abnormalities. The necessary tests for initial assessment and diagnosis of CLL consist of a complete blood count with differentials (CBC w/Diff), peripheral smear, and flow cytometry.<xref ref-type="bibr" rid="article-131137.r42">[42]</xref></p>
        <p>CLL is diagnosed using the updated 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) national cancer institute guidelines. As per the&#x000a0;criteria,&#x000a0;CLL is diagnosed with a peripheral blood monoclonal B-cell lymphocytosis more than or equal to 5,000 /microL [&#x02265; 5 &#x000d7; 109 /L] sustained for at least three months.&#x000a0;</p>
        <p>Peripheral blood smear findings include smudge cells, leukemic cells with a narrow border of cytoplasm, and a dense nucleus with indiscernible nucleoli. Clonality of the B lymphocytes is confirmed through flow cytometry on the peripheral blood or bone marrow aspirate, revealing immunoglobulin light chain restriction.</p>
        <p>Other findings include coexpression of B-cell-associated antigens (CD23, CD20, and CD19) and mature B and T-cell antigens (CD5). Sometimes, a biclonal population is identified, one with kappa and the other with lambda light chain restriction. A recent study estimated biclonality in 1.4% of CLL cases.<xref ref-type="bibr" rid="article-131137.r48">[48]</xref></p>
        <p>Peripheral blood&#x000a0;fluorescence in situ hybridization&#x000a0;(FISH) and next-generation sequencing (NGS) or Sanger sequencing analysis are useful prognostication tools and may affect treatment options. For instance, loss of ATM gene or identification of Del(11q22-23) and loss of TP53 or identification of Del(17p12), which leads to the loss of TP53, is associated with poor response to drugs whose mechanism of action involves DNA damage.<xref ref-type="bibr" rid="article-131137.r25">[25]</xref><xref ref-type="bibr" rid="article-131137.r26">[26]</xref>&#x000a0;Del(17p) and TP53 mutations are&#x000a0;estimated to affect&#x000a0;approximately 7 to 10% of treatment-naive CLL patients and 10-47% of all CLL patients, respectively.<xref ref-type="bibr" rid="article-131137.r49">[49]</xref><xref ref-type="bibr" rid="article-131137.r50">[50]</xref><xref ref-type="bibr" rid="article-131137.r51">[51]</xref>&#x000a0;</p>
        <p>NGS can also detect&#x000a0;immunoglobulin heavy chain variable region (IGHV) gene mutation as a 2% or more difference in nucleotide sequence compared to germline DNA. CLL with mutated IGHV are clinically less aggressive and have a low frequency of driver mutations.<xref ref-type="bibr" rid="article-131137.r29">[29]</xref><xref ref-type="bibr" rid="article-131137.r41">[41]</xref><xref ref-type="bibr" rid="article-131137.r52">[52]</xref></p>
      </sec>
      <sec id="article-131137.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Asymptomatic Patients</bold>
</p>
        <p>Patients without significant symptoms or laboratory abnormalities such as severe cytopenia or significant hypogammaglobulinemia are observed without treatment for signs of progression since there is no evidence to support clinical benefit. Rather treatment initiation in asymptomatic patients is associated with a risk of toxicity without clinical benefit.<xref ref-type="bibr" rid="article-131137.r53">[53]</xref><xref ref-type="bibr" rid="article-131137.r54">[54]</xref><xref ref-type="bibr" rid="article-131137.r55">[55]</xref>&#x000a0;</p>
        <p>International prognostic score (IPS-E) risk stratification, based on three risk factors: absolute lymphocyte count&#x000a0;greater than 15,000/microL, presence of palpable lymph nodes, and unmutated IGHV, is a valuable tool in predicting the likelihood of treatment initiation in asymptomatic patients.&#x000a0;Patients with no risk factors are considered low risk and have less than one percent likelihood of requiring treatment at one year and eight percent at five years. Those with one out of three risk factors are considered to be an intermediate risk, with three percent expected to require treatment by one year and twenty-eight percent at five years. Finally, those with two or three risk factors are considered high risk. It is expected that fourteen percent will need treatment at one year and sixty-one percent at five years.<xref ref-type="bibr" rid="article-131137.r56">[56]</xref></p>
        <p>
<bold>Symptomatic Disease</bold>
</p>
        <p>Treatment for CLL is indicated in patients with significant clinical symptoms from CLL or in the presence of laboratory abnormalities such as significant cytopenia and symptomatic hypogammaglobulinemia. The International Workshop on Chronic Lymphocytic Leukemia (iWCLL) requires the presence of at least one criterion to diagnose the active disease: signs of worsening marrow failure,&#x000a0;such as progressive or&#x000a0;new thrombocytopenia, anemia, splenomegaly, or lymphadenopathy that is symptomatic or progressive, autoimmune anemia or thrombocytopenia not responsive to steroids, extranodal involvement, and constitutional symptoms such as weight loss, severe fatigue, fevers or night sweats.<xref ref-type="bibr" rid="article-131137.r42">[42]</xref></p>
        <p>Multiple treatment combinations are available, but with limited evidence directly comparing the treatment options. Following are the important classes of drugs commonly used in the treatment of CLL:&#x000a0;BTK inhibitors (Bruton tyrosine kinase), including ibrutinib and acalabrutinib, BCL2 inhibitor venetoclax, anti-CD-20 monoclonal antibodies rituximab, ofatumumab, obinutuzumab, alkylating agents such as chlorambucil, cyclophosphamide, bendamustine and purine analogs such as fludarabine and pentostatin&#x000a0;</p>
        <p>Factors affecting the treatment selection include&#x000a0;stage, molecular and cytogenetic characteristics of the disease, patient fitness, and goals of care for treatment. Some important molecular and cytogenetic considerations impacting treatment selection are discussed below.&#x000a0;</p>
        <p>The presence of del 17p or TP53 mutations is associated with poor response to cytotoxic chemotherapeutic regimens, including purine analog-based regimens. However, there is clinical evidence supporting the efficacy of BTK inhibitors such as Ibrutinib and acalabrutinib and BCL-2 inhibitor venetoclax as monotherapy or in combination with anti-CD 20 monoclonal antibodies.<xref ref-type="bibr" rid="article-131137.r57">[57]</xref><xref ref-type="bibr" rid="article-131137.r58">[58]</xref><xref ref-type="bibr" rid="article-131137.r59">[59]</xref>&#x000a0;</p>
        <p>Another molecular factor predictive of treatment response is the IGHV mutation status. Unmutated IGHV is a marker of aggressive disease, and similar to TP53 or del 17p mutations, BCL-2 inhibitors and BTK inhibitors are effective in the presence of unmutated IGHV compared to purine analog-based regimens.<xref ref-type="bibr" rid="article-131137.r60">[60]</xref></p>
      </sec>
      <sec id="article-131137.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>&#x000a0;Differential diagnoses caused by clonal lymphocytosis include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Prolymphocytic Leukemia</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>The condition presents with lymphadenopathy and organomegaly. However, this condition differs from CLL as prolymphocytes in the smear differ from CLL cells.<xref ref-type="bibr" rid="article-131137.r61">[61]</xref><xref ref-type="bibr" rid="article-131137.r62">[62]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Hairy Cell Leukemia (HCL)</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>HCL can present with lymphocytosis, organomegaly, and cytopenias. However, HCL rarely presents with lymphadenopathy as opposed to CLL. Additionally, HCL immunophenotyping and smear will show distinct differences from CLL.<xref ref-type="bibr" rid="article-131137.r63">[63]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Follicular Lymphoma (FL)</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>FL presents similarly to CLL, with both tumor cells being similar in size and having similar clinical findings such as waxing and waning diffuse painless lymphadenopathy. However, it differs from CLL as biopsy will show a nodular growth pattern usually not seen in CLL. In cases where CLL does have a similar growth pattern to FL, further examination of FL cells will&#x000a0;reveal irregular nuclear centrocytes and larger centroblasts as opposed to CLL cells which have round to oval nuclei.<xref ref-type="bibr" rid="article-131137.r64">[64]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Lymphoplasmacytic Lymphoma (LPL)&#x000a0;</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>&#x000a0;LPL is a lymphoproliferative disorder that can present clinically similar to CLL.<xref ref-type="bibr" rid="article-131137.r42">[42]</xref><xref ref-type="bibr" rid="article-131137.r65">[65]</xref>&#x000a0;Laboratory findings will show that patients with LPL have a monoclonal paraprotein spike which can also be seen in CLL. Additionally, a minority of LPL can also be positive for CD5, as seen with CLL. However, both conditions can be differentiated as CLL&#x02019;s M-spike will be below 0.5g/dL as opposed to LPL, where M-spike is always over 0.5 g/dL.<xref ref-type="bibr" rid="article-131137.r66">[66]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Mantle Cell Lymphoma (MCL)</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>MCL can share clinical and morphological features with CLL as both conditions present a leukemic phase, cells with nuclear irregularities, and positive CD5 and CD20 markers. However, both conditions differ, with CLL cells having negative cyclin D1 and a large portion positive for CD23, as opposed to MCL, which has the complete opposite.<xref ref-type="bibr" rid="article-131137.r67">[67]</xref>&#x000a0;Furthermore, in cases where CLL and MCL share both cyclin D1 and CD23 findings, biopsies showing clear center lymphoid proliferation centers will exclude MCL.<xref ref-type="bibr" rid="article-131137.r68">[68]</xref>&#x000a0;Lastly, MCL will differ from CLL by having FISH studies positive for t(11:14).</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Splenic Marginal Zone Lymphoma (SMZL)</bold>&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>CLL and SMZL will both have peripheral smear lymphocytosis and share expression for CD5, CD43, CD23, and IgD. Additionally, both can also present with splenomegaly. However, SMZL can express CD20 and bright SmIg, both findings not seen in CLL.<xref ref-type="bibr" rid="article-131137.r69">[69]</xref><xref ref-type="bibr" rid="article-131137.r70">[70]</xref><xref ref-type="bibr" rid="article-131137.r71">[71]</xref>&#x000a0;Furthermore, CLL differs from SMZL in center lymphoid proliferation centers not seen in the latter.<xref ref-type="bibr" rid="article-131137.r72">[72]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Differential diagnoses caused by reactive lymphocytosis include infections. Infections in which lymphocytosis significantly occurs include pertussis, infectious mononucleosis, and toxoplasmosis. In viral infections, peripheral smear will show activated T cells as atypical lymphocytes, in which the cells have large cytoplasms containing azurophilic granules.&#x000a0;However, lymphocytosis is non-clonal and transient for all these infections, with white blood cell (WBC) counts normalizing within weeks, unlike in CLL, where lymphocytosis is clonal and persists for over three months. Furthermore, due to the non-clonal causes of lymphocytosis, immunophenotyping through flow cytometry will fail to show the diagnostic findings required for CLL.</p>
      </sec>
      <sec id="article-131137.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Research is still ongoing concerning optimal treatment selection and sequencing of various options in the course of treatment. For example, one recent study evaluated patients in the early stage of chronic lymphocytic leukemia who were not in an active disease state.<xref ref-type="bibr" rid="article-131137.r73">[73]</xref>&#x000a0;The study focused on chemotherapy compared to no intervention but rather an observation. When used in this population, ibrutinib leads to a delayed onset of progression to the active stage of the disease. It also leads to a decreased necessity for patients requiring more targeted therapies in the future for CLL.&#x000a0;</p>
        <p>However, findings on ibrutinib have also shown increased toxicity.&#x000a0;Unfortunately, the available research is still limited, and in this case, the long-term outcomes are unclear, including survival rates and widespread clinical application of these interventions early on. Therefore, guidelines remain that patients in early-stage who are not showing any signs of active disease should remain in observation.</p>
      </sec>
      <sec id="article-131137.s12" sec-type="Staging">
        <title>Staging</title>
        <p>Chronic lymphocytic leukemia&#x000a0;staging uses two stratification systems: Binet staging, primarily used in Europe, and the modified Rai-Sawitsky staging, primarily used in the United States. Both systems, as illustrated below, use a complete blood count and physical exam findings to stratify the patients into low, intermediate, and high-risk groups.<xref ref-type="bibr" rid="article-131137.r44">[44]</xref><xref ref-type="bibr" rid="article-131137.r43">[43]</xref></p>
        <p>
<bold>Modified Rai Clinical Staging System for CLL</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Low Risk:&#x000a0;</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Stage 0: Lymphocytosis in peripheral blood or bone marrow.&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Intermediate Risk:&#x000a0;</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Stage I: Lymphocytosis plus lymphadenopathy (enlarged lymph nodes).</p>
              </list-item>
              <list-item>
                <p>Stage II: Lymphocytosis plus hepatomegaly or splenomegaly with or without lymphadenopathy.&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>High Risk:</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Stage III: Lymphadenopathy plus anemia (hemoglobin &#x0003c; 11 g/dL) plus organomegaly (spleen or liver) with or without lymphadenopathy.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Stage IV: Lymphadenopathy plus thrombocytopenia (platelet &#x0003c;100,000/MCL) with or without organomegaly (spleen or liver) or lymphadenopathy.<xref ref-type="bibr" rid="article-131137.r43">[43]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Binet Staging System for CLL</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Low Risk</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Stage A: &#x02264; 2 involved sites of lymphoid enlargement* with no anemia or thrombocytopenia.&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Intermediate Risk</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Stage B: &#x02265; 3 lymphoid enlargement involved sites* with no anemia or thrombocytopenia.&#x000a0;&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>High Risk</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Stage C: Same lymphoid enlargement as stage A or B, but with the presence of anemia (hemoglobin &#x0003c; 10 g/dL) or thrombocytopenia (platelet &#x0003c; 100,000/mcL).<xref ref-type="bibr" rid="article-131137.r44">[44]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p><bold>*</bold>&#x000a0;Lymphoid-bearing sites: Cervical lymph nodes, axillary lymph nodes, inguinal-femoral lymph nodes, liver, and spleen<xref ref-type="bibr" rid="article-131137.r44">[44]</xref></p>
      </sec>
      <sec id="article-131137.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>CLL prognosis is largely determined by the Rai and Binet staging systems and other etiologies causing cytopenia, including marrow failure, autoimmune cytopenias, or prior therapy. A large retrospective study found that CLL patients with autoimmune cytopenias have an overall better prognosis when compared to bone marrow-induced cytopenias.<xref ref-type="bibr" rid="article-131137.r74">[74]</xref>&#x000a0;As detailed earlier under the staging section, the Rai and Binet systems relate directly to prognosis.</p>
        <p>A&#x000a0;published series from 1975 showed that Rai low-risk stage 0 comprised&#x000a0;18% of cases and had a historical median overall survival (OS) of over 150 months.<xref ref-type="bibr" rid="article-131137.r43">[43]</xref>&#x000a0;The intermediate risk, Rai stage I and stage II, comprised 23% and 31% of cases and an estimated median OS of 101 months and 71 months, respectively. At high risk, Rai stage III and IV comprised 17% and 11% of cases, respectively, and both had a median OS of 19 months.<xref ref-type="bibr" rid="article-131137.r43">[43]</xref></p>
        <p>As previously illustrated, the Binet staging system also risk stratifies patients into low, intermediate, and high-risk categories. Published data from 1981 showed that Binet stage A had a comparable median OS to age-matched controls, while stage B and stage C had a median OS of 84 and 24 months, respectively.<xref ref-type="bibr" rid="article-131137.r75">[75]</xref><xref ref-type="bibr" rid="article-131137.r44">[44]</xref></p>
        <p>Following the established Rai and Binet staging systems, other prognostic scores/indexes on further CLL variant genetics include the CLL international prognostic index (CLL-IPI), CLL1 prognostic model (CLL1-PM), International Prognostic Score for Early-stage CLL (IPS-E), and Four Factor Prognostic Model for Ibrutinib.</p>
        <p>
<bold>CLL-IPI</bold>
</p>
        <p>CLL-IPI's system parameter consists of 4 points for TP53 mutations or Del(17p), 2 points for &#x0003e;3.5 mg/L of serum beta-2 immunoglobulin, 2 points for unmutated IGHV, 1 point for intermediate or high-risk Binet or Rai staging, and 1 point for age greater than 65 years. The point score system divides into four different groups, with 0&#x000a0;to 1 point being low risk, 2&#x000a0;to 3 points being intermediate risk, 4&#x000a0;to 6 points being high risk, and 7&#x000a0;to 10 points being very high risk. The scoring system was established and validated from extensive studies, which showed the 5&#x000a0;to 10-year OS of low risk at 91 to 87%, intermediate risk at 80 to 40%, high risk at 53 to 16%, and very high risk at 19 to 0%.<xref ref-type="bibr" rid="article-131137.r76">[76]</xref></p>
        <p>
<bold>CLL1-PM</bold>
</p>
        <p>CLL1-PM and IPS-E are scores used for prognosis evaluation of early-stage CLL. CLL1-PM is a scoring system consisting of 14 points comprised of Del(17p) at 3.5 points, unmutated IGHV at 2.5 points, Del(11q) at 2.5 points, &#x0003e;3.5 mg/L of serum beta-2 microglobulin at 2.5 points, less than 12 months of lymphocyte doubling time at 1.5 points, and age greater than 60 years at 1.5 points. They are divided into very low risk at 0&#x000a0;to 1.5 points, low risk at 2&#x000a0;to 4 points, high risk at 4.5&#x000a0;to 6.5 points, and very high risk at 7&#x000a0;to 14 points, with their 5&#x000a0;to 10 year OS being 86 to 67%, 52 to 26%, 28 to 3%, and 11 to 0%, respectively.<xref ref-type="bibr" rid="article-131137.r77">[77]</xref><xref ref-type="bibr" rid="article-131137.r53">[53]</xref></p>
        <p>
<bold>IPS-E</bold>
</p>
        <p>The IPS-E stratifies CLL patients by three risk factors: palpable lymph nodes, lymphocytosis (&#x0003e;15,000/microL), and unmutated IGHV. Those with no risk factors are low risk, those with one risk factor are intermediate risk, and those with 2-3 risk factors are high risk. The three risk groups have shown that the 1-year likelihood percent of requiring treatment is less than 1%, 3%, and 14% for low risk, intermediate-risk, and high risk, respectively. For the 5-year likelihood percent of requiring treatment, data shows 8%, 28%, and 61% for low risk, intermediate-risk, and high risk, respectively.<xref ref-type="bibr" rid="article-131137.r56">[56]</xref></p>
        <p>
<bold>Four Factor Prognostic Model</bold>
</p>
        <p>The Four Factor Prognostic Model for Ibrutinib is a 4-point system consisting of 1-point variables of&#x0003e;250 units/L of lactate dehydrogenase, Del(17p) or TP53 mutations, &#x02265;5 mg/L serum beta-2 microglobulin, and refractory or relapsed disease.&#x000a0;Those with 0-1 points are low-risk, 2 points are intermediate-risk, and 3-4 points are high-risk. Data shows the 3-year OS is 93%, 83%, and 63% for low-risk, intermediate-risk, and high-risk groups, respectively.<xref ref-type="bibr" rid="article-131137.r78">[78]</xref></p>
        <p>Relating to CLL variant genetics, recent advancements in technology and science have provided markers that aid in predicting disease course and assessing disease prognosis, some aiding in both.<xref ref-type="bibr" rid="article-131137.r79">[79]</xref>&#x000a0;TP53 mutations and Del(17p), which lead to loss of Tp53 function, are two significant predictive markers, given that they predict worse outcomes with chemoimmunotherapy compared to targeted therapies such as BLC2 and BTK inhibitors. Additionally, TP53 mutations and Del(17p) are currently both prognostic markers used in all therapies available, as individuals with these markers have been found to have poorer outcomes when compared to those without them.<xref ref-type="bibr" rid="article-131137.r80">[80]</xref>&#x000a0;</p>
        <p>IGHV mutations are also important predictive markers, occurring in close to 50% of CLL tumors.<xref ref-type="bibr" rid="article-131137.r81">[81]</xref><xref ref-type="bibr" rid="article-131137.r82">[82]</xref><xref ref-type="bibr" rid="article-131137.r83">[83]</xref>&#x000a0;Complex karyotype with greater than five abnormalities predicts poor prognosis independent of TP53 or IgVH status.&#x000a0;From a predictive aspect, studies have shown that CLL patients with IGHV mutations have a prolonged-lasting disease remission status post chemoimmunotherapy compared to those with unmutated IGHV.</p>
        <p>Additionally, the CLL14 trial in 2020 showed that unmutated IGHV was a predictive marker for treatment benefits when comparing venetoclax with obinutuzumab to obinutuzumab with chlorambucil.<xref ref-type="bibr" rid="article-131137.r80">[80]</xref>&#x000a0;Also associated with unmutated IGHV are NOTCH1 mutations.&#x000a0;However, this marker's current data is unclear and is still under investigation for confirmatory findings.<xref ref-type="bibr" rid="article-131137.r76">[76]</xref></p>
        <p>The last predictive markers discussed include BLC2, BTK, and PLCg2 mutations, which can predict treatment efficacy and are often tested after initiating treatment. Specifically, studies have shown worse predicted clinical outcomes in those with BTK and PLCg2 mutations and status post-treatment with BCR inhibitors.&#x000a0;Regarding BCL2 mutations, studies have shown that those with the mutation and treated with venetoclax have worse predicted clinical outcomes when treated with venetoclax therapy again.<xref ref-type="bibr" rid="article-131137.r84">[84]</xref><xref ref-type="bibr" rid="article-131137.r85">[85]</xref><xref ref-type="bibr" rid="article-131137.r86">[86]</xref></p>
        <p>Lastly, two other factors associated with worsening prognosis include lymphocyte doubling time, particularly in less than 12 months, and Beta-2 microglobulin.<xref ref-type="bibr" rid="article-131137.r87">[87]</xref><xref ref-type="bibr" rid="article-131137.r88">[88]</xref></p>
      </sec>
      <sec id="article-131137.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Infections are one of the most common complications of chronic lymphocytic leukemia, both before&#x000a0;and post-treatment, due to an abnormal functioning humoral and cell-mediated immune system. Mainly due to the immunocompromised state from both disease and treatments, patients are primarily susceptible to opportunistic infections such as herpes simplex virus, cytomegalovirus, pneumocystis jirovecii, Aspergillus, and mycobacterial pathogens.<xref ref-type="bibr" rid="article-131137.r89">[89]</xref><xref ref-type="bibr" rid="article-131137.r90">[90]</xref><xref ref-type="bibr" rid="article-131137.r91">[91]</xref><xref ref-type="bibr" rid="article-131137.r92">[92]</xref></p>
        <p>Hematologic complications are often seen, given the nature of the disease.&#x000a0;Anemia is one of CLL's most common complications, mainly due to marrow infiltration from disease progression, marrow suppression from chemotherapy, autoimmune hemolytic anemia, hypersplenism, red cell aplasia, and gastrointestinal blood loss due to treatments and disease complications. Autoimmune hemolytic anemia is estimated to occur in approximately 4 to 10% of CLL cases throughout the disease course.<xref ref-type="bibr" rid="article-131137.r93">[93]</xref><xref ref-type="bibr" rid="article-131137.r94">[94]</xref>&#x000a0;</p>
        <p>Red cell aplasia is somewhat of a rare complication, with incidence not fully understood at this time; however, it is estimated to occur in 0.5% of CLL cases.<xref ref-type="bibr" rid="article-131137.r95">[95]</xref>&#x000a0;Thrombocytopenia can present as a complication at any time throughout the disease course from many etiologies, including disease burden on platelet suppression, treatments, infections, and autoimmune disease.&#x000a0;Immune thrombocytopenia (ITP) is a significant complication, occurring in 2 to 5% of CLL cases.<xref ref-type="bibr" rid="article-131137.r96">[96]</xref>&#x000a0;Leukostasis is a complication that is a medical emergency and typically becomes symptomatic when WBC counts exceed 400,000/microL.&#x000a0;</p>
        <p>Gastrointestinal-related complications from CLL treatments include severe colitis and life-threatening diarrhea due to idelalisib and phosphoinositide 3-kinase (PI3K) delta inhibitor. Furthermore, Idelalisib can also cause hepatotoxicity. In addition to gastrointestinal involvement, pneumonitis is another potentially fatal treatment complication of idelalisib and ibrutinib.<xref ref-type="bibr" rid="article-131137.r97">[97]</xref></p>
        <p>Secondary cancers related to CLL are largely hematologic and solid malignancies, including colon, lung, prostate, and breast.<xref ref-type="bibr" rid="article-131137.r98">[98]</xref>&#x000a0;Furthermore, aggressive lymphoma, commonly known as Richter syndrome or Richter transformation, occurs in approximately 1 to 10% of CLL cases.<xref ref-type="bibr" rid="article-131137.r99">[99]</xref><xref ref-type="bibr" rid="article-131137.r100">[100]</xref></p>
      </sec>
      <sec id="article-131137.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Education plays a significant role in caring for patients with chronic lymphocytic leukemia. It begins from the diagnosis and continues throughout the patient's disease course. It must be carried out as a multidisciplinary approach, including all the healthcare workers the patient encounters. The importance of proper education is especially highlighted in patients diagnosed at an early stage and without active disease. In these patients, evidence-based research supports observation and no intervention.<xref ref-type="bibr" rid="article-131137.r42">[42]</xref>&#x000a0;</p>
        <p>Providing the appropriate and necessary education to the patient, family members, or caregivers as to why observation is the ideal course at that moment can create a very frustrating situation for those seeking immediate intervention. Additionally, it is also vital to discuss opportunities such as clinical trials. In some circumstances, even though observation is the recommendation, some patients can still be eligible for clinical trials.</p>
        <p>Lastly,&#x000a0;it is essential for physicians caring for patients with CLL to keep up-to-date on available clinical trials, research, and updates in management recommendations. Although this is, in general, a necessary medical concept, it is particularly significant for CLL given ongoing investigations, evolving guidelines, and medication availability.</p>
      </sec>
      <sec id="article-131137.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Optimizing patient care for chronic lymphocytic leukemia requires interprofessional communication between clinicians (MDs, DOs, NPS, and PAs) of different specialties, including primary care clinicians, hematology, and oncology. Care coordination among nursing staff, home health care support teams, pharmacists, case management, and social workers is crucial.</p>
        <p>Oncology specialized pharmacists can make critical contributions, coordinating their input with the clinicians ordering drugs, verifying appropriate dosing, performing medication reconciliation, and providing counsel to patients and nurses. Other considerations that could enhance patient-centered care include support from hospice care teams, psychiatry, therapists, or mental health professionals.</p>
        <p>All interprofessional team members must maintain accurate and up-to-date records of every interaction or intervention with the patient, including any status changes. This will permit every team member to have the latest accurate patient case data. Any concerns must be immediately communicated to other team members to implement coordinated interventions if necessary. This interprofessional approach will yield the best possible outcomes for CLL patients. [Level 5]</p>
        <p>Participation in clinical trials should be encouraged whenever available and feasible. Continued medical education on the latest developments, clinical trial options, and ongoing research are encouraged, given the rapidly changing nature of the field of the disease.</p>
      </sec>
      <sec id="article-131137.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131137&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131137">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/chronic-lymphocytic-leukemia-with-variant-genetics-genetic-contributions-of-chronic-leukemia-of-leukocytes/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=131137">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/131137/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=131137">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-131137.s18">
        <title>References</title>
        <ref id="article-131137.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kikushige</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.</article-title>
            <source>J Clin Exp Hematop</source>
            <year>2020</year>
            <month>Dec</month>
            <day>15</day>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>146</fpage>
            <page-range>146-158</page-range>
            <pub-id pub-id-type="pmid">33148933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.</article-title>
            <source>Am J Hematol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>94</volume>
            <issue>11</issue>
            <fpage>1266</fpage>
            <page-range>1266-1287</page-range>
            <pub-id pub-id-type="pmid">31364186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer statistics, 2022.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-33</page-range>
            <pub-id pub-id-type="pmid">35020204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>The pathogenesis of chronic lymphocytic leukemia.</article-title>
            <source>Annu Rev Pathol</source>
            <year>2014</year>
            <volume>9</volume>
            <fpage>103</fpage>
            <page-range>103-18</page-range>
            <pub-id pub-id-type="pmid">23987584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Law</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Berndt</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Speedy</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Camp</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sava</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Skibola</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Holroyd</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sunter</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Nieters</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Monnereau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin-Garcia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldin</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Clot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Teras</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Quintela</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Birmann</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cozen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Majid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smedby</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Dearden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brooks-Wilson</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Purdue</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Mainou-Fowler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vajdic</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Cocco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Call</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Liebow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Melbye</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glimelius</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mansouri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Diver</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Conde</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bracci</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Holly</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Tinker</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Benavente</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Boffetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maynadie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Albanes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Caporaso</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Severson</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Riboli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vineis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Southey</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Milne</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Clavel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Topka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spinelli</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ennas</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Summerfield</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Miligi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pettitt</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>North</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Allsup</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Fraumeni</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Offit</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hjalgrim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pepper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chanock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Fegan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosenquist</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Sanjose</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carracedo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dyer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rothman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Houlston</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Slager</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.</article-title>
            <source>Nat Commun</source>
            <year>2017</year>
            <month>Feb</month>
            <day>06</day>
            <volume>8</volume>
            <fpage>14175</fpage>
            <pub-id pub-id-type="pmid">28165464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldin</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hemminki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>Sep</month>
            <day>15</day>
            <volume>104</volume>
            <issue>6</issue>
            <fpage>1850</fpage>
            <page-range>1850-4</page-range>
            <pub-id pub-id-type="pmid">15161669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Land</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Leukemias, myeloma, and other lymphoreticular neoplasms.</article-title>
            <source>Cancer</source>
            <year>1995</year>
            <month>Jan</month>
            <day>01</day>
            <volume>75</volume>
            <issue>1 Suppl</issue>
            <fpage>381</fpage>
            <page-range>381-94</page-range>
            <pub-id pub-id-type="pmid">8001009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Speedy</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Beekman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chapaprieta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Garc&#x000ed;a</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez-Abril</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Be&#x000e0;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Puiggr&#x000f2;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Torrents</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Puente</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Ot&#x000ed;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Houlston</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Subero</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics.</article-title>
            <source>Nat Commun</source>
            <year>2019</year>
            <month>Aug</month>
            <day>09</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>3615</fpage>
            <pub-id pub-id-type="pmid">31399598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Croce</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Packham</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gribben</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Chronic lymphocytic leukaemia.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Jan</month>
            <day>19</day>
            <volume>3</volume>
            <fpage>16096</fpage>
            <pub-id pub-id-type="pmid">28102226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Holm</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Verkasalo</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Iliadou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaprio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koskenvuo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pukkala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Skytthe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hemminki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Jul</month>
            <day>13</day>
            <volume>343</volume>
            <issue>2</issue>
            <fpage>78</fpage>
            <page-range>78-85</page-range>
            <pub-id pub-id-type="pmid">10891514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumann Kreuziger</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Tarchand</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>The impact of Agent Orange exposure on presentation and prognosis of patients with chronic lymphocytic leukemia.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-6</page-range>
            <pub-id pub-id-type="pmid">23573826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Global Burden of Disease Cancer Collaboration</collab>
              <name>
                <surname>Fitzmaurice</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barber</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Barregard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bhutta</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dicker</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chimed-Orchir</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dandona</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dandona</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Forouzanfar</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hunter-Merrill</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hosgood</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Khubchandani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kutz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>MacIntyre</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Marczak</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marquez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mokdad</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Pinho</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pourmalek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sanabria</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sandar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sartorius</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Shackelford</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Shibuya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stanaway</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vollset</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Westerman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zeeb</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zoeckler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abd-Allah</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Alabed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alam</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Aldhahri</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Alem</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alemayohu</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Al-Raddadi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amare</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amoako</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Artaman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asayesh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Atnafu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Awasthi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saleem</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Barac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bedi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bensenor</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Berhane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernab&#x000e9;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Betsu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Binagwaho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boneya</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Campos-Nonato</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda-Orjuela</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Catal&#x000e1;-L&#x000f3;pez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chibueze</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chitheer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Cowie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Damtew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>das Neves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dharmaratne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Driscoll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ekwueme</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Endries</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Farvid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farzadfar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>G/Hiwot</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Gebru</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gopalani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hailu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Horino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horita</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Husseini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huybrechts</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Islami</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jakovljevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Javanbakht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kasaeian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kedir</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Khader</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Khang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leigh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lunevicius</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>El Razek</surname>
                <given-names>HMA</given-names>
              </name>
              <name>
                <surname>Malekzadeh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malta</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Marcenes</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Markos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Melaku</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Meles</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Mendoza</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mengiste</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Meretoja</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Mohammad</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moradi-Lakeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nand</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Nguyen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Nolte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ogbo</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Oladimeji</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Oren</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Plass</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Qorbani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radfar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rafay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>S&#x000f8;reide</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Satpathy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sawhney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sepanlou</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>She</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shiue</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Shrime</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soneji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stathopoulou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stroumpoulis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sufiyan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Sykes</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Tabar&#x000e9;s-Seisdedos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tadese</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tedla</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Tessema</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>BX</given-names>
              </name>
              <name>
                <surname>Ukwaja</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Uzochukwu</surname>
                <given-names>BSC</given-names>
              </name>
              <name>
                <surname>Vlassov</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Weiderpass</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wubshet Terefe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yebyo</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Yimam</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Yonemoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Younis</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zaidi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zaki</surname>
                <given-names>MES</given-names>
              </name>
              <name>
                <surname>Zenebe</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>CJL</given-names>
              </name>
              <name>
                <surname>Naghavi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.</article-title>
            <source>JAMA Oncol</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>524</fpage>
            <page-range>524-548</page-range>
            <pub-id pub-id-type="pmid">27918777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Tien</surname>
                <given-names>HF</given-names>
              </name>
            </person-group>
            <article-title>The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Nov</month>
            <day>25</day>
            <volume>116</volume>
            <issue>22</issue>
            <fpage>4430</fpage>
            <page-range>4430-5</page-range>
            <pub-id pub-id-type="pmid">20713960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miranda-Filho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;eros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferlay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soerjomataram</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Monnereau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological patterns of leukaemia in 184 countries: a population-based study.</article-title>
            <source>Lancet Haematol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>e14</fpage>
            <page-range>e14-e24</page-range>
            <pub-id pub-id-type="pmid">29304322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of lymphomas and leukaemias in Africa--an overview.</article-title>
            <source>Leuk Res</source>
            <year>1985</year>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>735</fpage>
            <page-range>735-40</page-range>
            <pub-id pub-id-type="pmid">2989624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oloo</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ogada</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Chronic lymphocytic leukaemia (CLL): clinical study at Kenyatta National Hospital (KNH).</article-title>
            <source>East Afr Med J</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>61</volume>
            <issue>11</issue>
            <fpage>797</fpage>
            <page-range>797-801</page-range>
            <pub-id pub-id-type="pmid">6535701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allemani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tereanu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Angelis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Capocaccia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Marcos-Gragera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maynadi&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lutz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Berrino</surname>
                <given-names>F</given-names>
              </name>
              <collab>HAEMACARE Working Group</collab>
            </person-group>
            <article-title>Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Nov</month>
            <day>11</day>
            <volume>116</volume>
            <issue>19</issue>
            <fpage>3724</fpage>
            <page-range>3724-34</page-range>
            <pub-id pub-id-type="pmid">20664057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patmore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.</article-title>
            <source>Br J Cancer</source>
            <year>2011</year>
            <month>Nov</month>
            <day>22</day>
            <volume>105</volume>
            <issue>11</issue>
            <fpage>1684</fpage>
            <page-range>1684-92</page-range>
            <pub-id pub-id-type="pmid">22045184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.</article-title>
            <source>Cancer Causes Control</source>
            <year>2008</year>
            <month>May</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-90</page-range>
            <pub-id pub-id-type="pmid">18064533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strati</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shanafelt</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Jul</month>
            <day>23</day>
            <volume>126</volume>
            <issue>4</issue>
            <fpage>454</fpage>
            <page-range>454-62</page-range>
            <pub-id pub-id-type="pmid">26065657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calin</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Dumitru</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bichi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zupo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aldler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rattan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rassenti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Negrini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bullrich</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Croce</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2002</year>
            <month>Nov</month>
            <day>26</day>
            <volume>99</volume>
            <issue>24</issue>
            <fpage>15524</fpage>
            <page-range>15524-9</page-range>
            <pub-id pub-id-type="pmid">12434020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hockenbery</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nu&#x000f1;ez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Milliman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Korsmeyer</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.</article-title>
            <source>Nature</source>
            <year>1990</year>
            <month>Nov</month>
            <day>22</day>
            <volume>348</volume>
            <issue>6299</issue>
            <fpage>334</fpage>
            <page-range>334-6</page-range>
            <pub-id pub-id-type="pmid">2250705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsagiopoulou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chapaprieta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Duran-Ferrer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moysiadis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Psomopoulos</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kollia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papakonstantinou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stamatopoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martin-Subero</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation.</article-title>
            <source>Haematologica</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>2864</fpage>
            <page-range>2864-2867</page-range>
            <pub-id pub-id-type="pmid">33256389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ambrose</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gatti</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>May</month>
            <day>16</day>
            <volume>121</volume>
            <issue>20</issue>
            <fpage>4036</fpage>
            <page-range>4036-45</page-range>
            <pub-id pub-id-type="pmid">23440242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kastan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Onyekwere</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sidransky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vogelstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Participation of p53 protein in the cellular response to DNA damage.</article-title>
            <source>Cancer Res</source>
            <year>1991</year>
            <month>Dec</month>
            <day>01</day>
            <volume>51</volume>
            <issue>23 Pt 1</issue>
            <fpage>6304</fpage>
            <page-range>6304-11</page-range>
            <pub-id pub-id-type="pmid">1933891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuerbitz</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Plunkett</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Kastan</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Wild-type p53 is a cell cycle checkpoint determinant following irradiation.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1992</year>
            <month>Aug</month>
            <day>15</day>
            <volume>89</volume>
            <issue>16</issue>
            <fpage>7491</fpage>
            <page-range>7491-5</page-range>
            <pub-id pub-id-type="pmid">1323840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nadeu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Royo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stankovic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pinyol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jares</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Garc&#x000ed;a</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Be&#x000e0;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Salaverria</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Oldreive</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aymerich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez-Cisneros</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rozman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villamor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Colomer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alcoceba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terol</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Colado</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Puente</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Ot&#x000ed;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Enjuanes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Apr</month>
            <day>28</day>
            <volume>127</volume>
            <issue>17</issue>
            <fpage>2122</fpage>
            <page-range>2122-30</page-range>
            <pub-id pub-id-type="pmid">26837699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>CLL clonal heterogeneity: an ecology of competing subpopulations.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Nov</month>
            <day>15</day>
            <volume>120</volume>
            <issue>20</issue>
            <fpage>4117</fpage>
            <page-range>4117-8</page-range>
            <pub-id pub-id-type="pmid">23160186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puente</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>Be&#x000e0;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vald&#x000e9;s-Mas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Villamor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez-Abril</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Subero</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Munar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rubio-P&#x000e9;rez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jares</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aymerich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Beekman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Belver</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carrio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castellano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Clot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Colado</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colomer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Enjuanes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estivill</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ferrando</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Gelp&#x000ed;</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gut</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Rivas</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Guerra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Garc&#x000ed;a</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nicol&#x000e1;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Orozco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Payer</surname>
                <given-names>&#x000c1;R</given-names>
              </name>
              <name>
                <surname>Pinyol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pisano</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Puente</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Queir&#x000f3;s</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Quesada</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Romeo-Casabona</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Royo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Royo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rozman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russi&#x000f1;ol</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Salaverr&#x000ed;a</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stamatopoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stunnenberg</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Tamborero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Terol</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Valencia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Bigas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Torrents</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gut</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Ot&#x000ed;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Non-coding recurrent mutations in chronic lymphocytic leukaemia.</article-title>
            <source>Nature</source>
            <year>2015</year>
            <month>Oct</month>
            <day>22</day>
            <volume>526</volume>
            <issue>7574</issue>
            <fpage>519</fpage>
            <page-range>519-24</page-range>
            <pub-id pub-id-type="pmid">26200345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landau</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Tausch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taylor-Weiner</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kluth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bozic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>B&#x000f6;ttcher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Cibulskis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sougnez</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Edelmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kless</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kneba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ritgen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lander</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Getz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Mutations driving CLL and their evolution in progression and relapse.</article-title>
            <source>Nature</source>
            <year>2015</year>
            <month>Oct</month>
            <day>22</day>
            <volume>526</volume>
            <issue>7574</issue>
            <fpage>525</fpage>
            <page-range>525-30</page-range>
            <pub-id pub-id-type="pmid">26466571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khiabanian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ciardullo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruscaggin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fam&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deambrogi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Paoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gattei</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guarini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fo&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rabadan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Apr</month>
            <day>03</day>
            <volume>123</volume>
            <issue>14</issue>
            <fpage>2139</fpage>
            <page-range>2139-47</page-range>
            <pub-id pub-id-type="pmid">24501221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fangazio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forconi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marasca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Laurenti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bruscaggin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cerri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cresta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fam&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Paoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bulian</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gattei</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guarini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deaglio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Capello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rabadan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pasqualucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dalla-Favera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fo&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Jan</month>
            <day>12</day>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>521</fpage>
            <page-range>521-9</page-range>
            <pub-id pub-id-type="pmid">22077063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stojanov</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sougnez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sivachenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeLuca</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vartanov</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Folco</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Cibulskis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sievers</surname>
                <given-names>QL</given-names>
              </name>
              <name>
                <surname>Shefler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hacohen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meyerson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Golub</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Lander</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Neuberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Getz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Dec</month>
            <day>29</day>
            <volume>365</volume>
            <issue>26</issue>
            <fpage>2497</fpage>
            <page-range>2497-506</page-range>
            <pub-id pub-id-type="pmid">22150006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oscier</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Rose-Zerilli</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Winkelmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gonzalez de Castro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Forster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gardiner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Else</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Strefford</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Jan</month>
            <day>17</day>
            <volume>121</volume>
            <issue>3</issue>
            <fpage>468</fpage>
            <page-range>468-75</page-range>
            <pub-id pub-id-type="pmid">23086750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fulci</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chiaretti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azzalin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carucci</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tavolaro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Castellano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Magrelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Citarella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maggio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peragine</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Santangelo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mauro</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Landgraf</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tuschl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ju</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sheridan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zavolan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guarini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fo&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Macino</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Jun</month>
            <day>01</day>
            <volume>109</volume>
            <issue>11</issue>
            <fpage>4944</fpage>
            <page-range>4944-51</page-range>
            <pub-id pub-id-type="pmid">17327404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrajoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shanafelt</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Ivan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Nouraee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ikuo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rassenti</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reuben</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Calin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Estrov</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Calin</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Sep</month>
            <day>12</day>
            <volume>122</volume>
            <issue>11</issue>
            <fpage>1891</fpage>
            <page-range>1891-9</page-range>
            <pub-id pub-id-type="pmid">23821659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sampath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vasan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sulda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Puduvalli</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Feb</month>
            <day>02</day>
            <volume>119</volume>
            <issue>5</issue>
            <fpage>1162</fpage>
            <page-range>1162-72</page-range>
            <pub-id pub-id-type="pmid">22096249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corney</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Flesken-Nikitin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nikitin</surname>
                <given-names>AY</given-names>
              </name>
            </person-group>
            <article-title>MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.</article-title>
            <source>Cancer Res</source>
            <year>2007</year>
            <month>Sep</month>
            <day>15</day>
            <volume>67</volume>
            <issue>18</issue>
            <fpage>8433</fpage>
            <page-range>8433-8</page-range>
            <pub-id pub-id-type="pmid">17823410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mraz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rassenti</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Ghia</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jepsen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Messer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frazer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Jul</month>
            <day>03</day>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-95</page-range>
            <pub-id pub-id-type="pmid">24787006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woyach</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The B-cell receptor signaling pathway as a therapeutic target in CLL.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Aug</month>
            <day>09</day>
            <volume>120</volume>
            <issue>6</issue>
            <fpage>1175</fpage>
            <page-range>1175-84</page-range>
            <pub-id pub-id-type="pmid">22715122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delgado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nadeu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Colomer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.</article-title>
            <source>Haematologica</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>105</volume>
            <issue>9</issue>
            <fpage>2205</fpage>
            <page-range>2205-2217</page-range>
            <pub-id pub-id-type="pmid">33054046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cheson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caligaris-Cappio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dighiero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hillmen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montserrat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chiorazzi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Jun</month>
            <day>21</day>
            <volume>131</volume>
            <issue>25</issue>
            <fpage>2745</fpage>
            <page-range>2745-2760</page-range>
            <pub-id pub-id-type="pmid">29540348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rai</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Sawitsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cronkite</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Chanana</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Pasternack</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Clinical staging of chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>1975</year>
            <month>Aug</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-34</page-range>
            <pub-id pub-id-type="pmid">1139039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Binet</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Auquier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dighiero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chastang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Piguet</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goasguen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vaugier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Potron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Colona</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oberling</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tchernia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jacquillat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boivin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lesty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Duault</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Monconduit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belabbes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gremy</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.</article-title>
            <source>Cancer</source>
            <year>1981</year>
            <month>Jul</month>
            <day>01</day>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>198</fpage>
            <page-range>198-206</page-range>
            <pub-id pub-id-type="pmid">7237385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agnew</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Ruchlemer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Matutes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bunker</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous findings in chronic lymphocytic leukaemia.</article-title>
            <source>Br J Dermatol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>150</volume>
            <issue>6</issue>
            <fpage>1129</fpage>
            <page-range>1129-35</page-range>
            <pub-id pub-id-type="pmid">15214899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazarian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Munger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quinquenel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dilhuydy</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Veronese</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luque Paz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gui&#x000e8;ze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ledoux-Pilon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paillassa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Merabet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vial</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bidet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waultier Rascalou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Broseus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roos-Weil</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lavaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Laribi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hivert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Friedrich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carpentier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ysebaert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Van Den Neste</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Willems</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Corby</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poulain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eclache</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maubec</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feugier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baran-Marszak</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lepr&#x000ea;tre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cymbalista</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).</article-title>
            <source>Am J Hematol</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>96</volume>
            <issue>9</issue>
            <fpage>E353</fpage>
            <page-range>E353-E356</page-range>
            <pub-id pub-id-type="pmid">34152612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Dessypris</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>Chronic lymphocytic leukemia with hyperleukocytosis. The hyperviscosity syndrome.</article-title>
            <source>Cancer</source>
            <year>1985</year>
            <month>Dec</month>
            <day>15</day>
            <volume>56</volume>
            <issue>12</issue>
            <fpage>2865</fpage>
            <page-range>2865-9</page-range>
            <pub-id pub-id-type="pmid">4052958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kern</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bacher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schnittger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dicker</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alpermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haferlach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haferlach</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization.</article-title>
            <source>Br J Haematol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>164</volume>
            <issue>4</issue>
            <fpage>565</fpage>
            <page-range>565-9</page-range>
            <pub-id pub-id-type="pmid">24236747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bentz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Benner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cabot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schlenk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Volkmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galle</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Poustka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunstein</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lichter</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.</article-title>
            <source>Blood</source>
            <year>1995</year>
            <month>Mar</month>
            <day>15</day>
            <volume>85</volume>
            <issue>6</issue>
            <fpage>1580</fpage>
            <page-range>1580-9</page-range>
            <pub-id pub-id-type="pmid">7888675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>el Rouby</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Potmesil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>EW</given-names>
              </name>
            </person-group>
            <article-title>p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.</article-title>
            <source>Blood</source>
            <year>1993</year>
            <month>Dec</month>
            <day>01</day>
            <volume>82</volume>
            <issue>11</issue>
            <fpage>3452</fpage>
            <page-range>3452-9</page-range>
            <pub-id pub-id-type="pmid">8241511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cordone</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Masi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mauro</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Soddu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morsilli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vegna</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Guglielmi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giuliacci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sacchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mandelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Foa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.</article-title>
            <source>Blood</source>
            <year>1998</year>
            <month>Jun</month>
            <day>01</day>
            <volume>91</volume>
            <issue>11</issue>
            <fpage>4342</fpage>
            <page-range>4342-9</page-range>
            <pub-id pub-id-type="pmid">9596683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mauro</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Anselmo</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Cimino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alimena</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Amadori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D'Arcangelo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giannarelli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bosi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bellesi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Acute leukaemia in patients treated for Hodgkin's disease.</article-title>
            <source>Br J Haematol</source>
            <year>1984</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-52</page-range>
            <pub-id pub-id-type="pmid">6466571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoechstetter</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>B&#x000fc;hler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eckart</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vehling-Kaiser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schimke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hurtz</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hopfinger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fuss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abenhardt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Blau</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Freier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goebeler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wendtner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bentz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emmerich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.</article-title>
            <source>Leukemia</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>2833</fpage>
            <page-range>2833-2837</page-range>
            <pub-id pub-id-type="pmid">28804126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herling</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cymbalista</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gro&#x000df;-Ophoff-M&#x000fc;ller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robrecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Langerbeins</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al-Sawaf</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porcher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cazin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dreyfus</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ibach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lepr&#x000ea;tre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wentner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hoechstetter</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kneba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Letestu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>B&#x000f6;ttcher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.</article-title>
            <source>Leukemia</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>2038</fpage>
            <page-range>2038-2050</page-range>
            <pub-id pub-id-type="pmid">32071431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <article-title>Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>1999</year>
            <month>May</month>
            <day>19</day>
            <volume>91</volume>
            <issue>10</issue>
            <fpage>861</fpage>
            <page-range>861-8</page-range>
            <pub-id pub-id-type="pmid">10340906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Condoluci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terzi di Bergamo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Langerbeins</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hoechstetter</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Herling</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>De Paoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doubek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mauro</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Chiodin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mattsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cutrona</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kotaskova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deambrogi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smedby</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bruscaggin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Moia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gillessen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghielmini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stussi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Neri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrarini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenquist</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Forconi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fo&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pospisilova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morabito</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Montserrat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2020</year>
            <month>May</month>
            <day>21</day>
            <volume>135</volume>
            <issue>21</issue>
            <fpage>1859</fpage>
            <page-range>1859-1869</page-range>
            <pub-id pub-id-type="pmid">32267500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al-Sawaf</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robrecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Warburton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Samoylova</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Liberati</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pinilla-Ibarz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Opat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sivcheva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Le D&#x000fb;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fogliatto</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Niemann</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Weinkove</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Boettcher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tausch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Humerickhouse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wendtner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Langerak</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Kreuzer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ritgen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goede</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mobasher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jun</month>
            <day>06</day>
            <volume>380</volume>
            <issue>23</issue>
            <fpage>2225</fpage>
            <page-range>2225-2236</page-range>
            <pub-id pub-id-type="pmid">31166681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Sawaf</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lilienweiss</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robrecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Patz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schary</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ritgen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tausch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kreuzer</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2020</year>
            <month>Mar</month>
            <day>12</day>
            <volume>135</volume>
            <issue>11</issue>
            <fpage>866</fpage>
            <page-range>866-870</page-range>
            <pub-id pub-id-type="pmid">31990291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Sawaf</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sail</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kutsch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wendtner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.</article-title>
            <source>Am J Hematol</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>96</volume>
            <issue>9</issue>
            <fpage>1112</fpage>
            <page-range>1112-1119</page-range>
            <pub-id pub-id-type="pmid">34050972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pepper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Majid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Hewamana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Walewska</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gesk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miall</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gardiner</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hills</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Dyer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Oscier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fegan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Defining the prognosis of early stage chronic lymphocytic leukaemia patients.</article-title>
            <source>Br J Haematol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>156</volume>
            <issue>4</issue>
            <fpage>499</fpage>
            <page-range>499-507</page-range>
            <pub-id pub-id-type="pmid">22171799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melo</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Galton</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group.</article-title>
            <source>Br J Haematol</source>
            <year>1986</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>377</fpage>
            <page-range>377-87</page-range>
            <pub-id pub-id-type="pmid">3487341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampert</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Child</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Galton</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The histopathology of prolymphocytic leukaemia with particular reference to the spleen: a comparison with chronic lymphocytic leukaemia.</article-title>
            <source>Histopathology</source>
            <year>1980</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-19</page-range>
            <pub-id pub-id-type="pmid">7353816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hairy-cell leukaemia and prolymphocytic leukaemia.</article-title>
            <source>Clin Haematol</source>
            <year>1977</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>245</fpage>
            <page-range>245-68</page-range>
            <pub-id pub-id-type="pmid">334414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathwani</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Diebold</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Drachenberg</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>MacLennan</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Hermelink</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Ullrich</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project.</article-title>
            <source>Hum Pathol</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-8</page-range>
            <pub-id pub-id-type="pmid">10088543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vitolo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Montoto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-85</page-range>
            <pub-id pub-id-type="pmid">18499469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Anagnostopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Treon</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of Waldenstrom's macroglobulinemia.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Mar</month>
            <day>01</day>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>1564</fpage>
            <page-range>1564-77</page-range>
            <pub-id pub-id-type="pmid">15735132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DiRaimondo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Albitar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giustolisi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease.</article-title>
            <source>Cancer</source>
            <year>2002</year>
            <month>Mar</month>
            <day>15</day>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>1721</fpage>
            <page-range>1721-30</page-range>
            <pub-id pub-id-type="pmid">11920534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perry</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bast</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Diffuse intermediate lymphocytic lymphoma. A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma.</article-title>
            <source>Cancer</source>
            <year>1990</year>
            <month>Nov</month>
            <day>01</day>
            <volume>66</volume>
            <issue>9</issue>
            <fpage>1995</fpage>
            <page-range>1995-2000</page-range>
            <pub-id pub-id-type="pmid">2224798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savilo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mollejo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinyol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piris</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zukerberg</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>WI</given-names>
              </name>
              <name>
                <surname>Koelliker</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Absence of cyclin D1 protein expression in splenic marginal zone lymphoma.</article-title>
            <source>Mod Pathol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>601</fpage>
            <page-range>601-6</page-range>
            <pub-id pub-id-type="pmid">9688179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Felman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Callet-Bauchu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Traverse-Glehen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Splenic marginal-zone lymphoma: a distinct clinical and pathological entity.</article-title>
            <source>Lancet Oncol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-103</page-range>
            <pub-id pub-id-type="pmid">12573351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gruszka-Westwood</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Matutes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coignet</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wotherspoon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH.</article-title>
            <source>Br J Haematol</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>104</volume>
            <issue>3</issue>
            <fpage>600</fpage>
            <page-range>600-4</page-range>
            <pub-id pub-id-type="pmid">10086800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isaacson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Matutes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The histopathology of splenic lymphoma with villous lymphocytes.</article-title>
            <source>Blood</source>
            <year>1994</year>
            <month>Dec</month>
            <day>01</day>
            <volume>84</volume>
            <issue>11</issue>
            <fpage>3828</fpage>
            <page-range>3828-34</page-range>
            <pub-id pub-id-type="pmid">7949139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langerbeins</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Robrecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cramer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>F&#x000fc;rstenau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Sawaf</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>von Tresckow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kreuzer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Vehling-Kaiser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Tausch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Eckart</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Schlag</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Freier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gaska</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Balser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reiser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stauch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wendtner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The CLL12 trial: ibrutinib vs placebo in treatment-na&#x000ef;ve, early-stage chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2022</year>
            <month>Jan</month>
            <day>13</day>
            <volume>139</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-187</page-range>
            <pub-id pub-id-type="pmid">34758069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hodgson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ferrer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Filella</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Montserrat</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Dec</month>
            <day>02</day>
            <volume>116</volume>
            <issue>23</issue>
            <fpage>4771</fpage>
            <page-range>4771-6</page-range>
            <pub-id pub-id-type="pmid">20736453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Binet</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Leporrier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dighiero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Charron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D'Athis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaugier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Beral</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Natali</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Raphael</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nizet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Follezou</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>A clinical staging system for chronic lymphocytic leukemia: prognostic significance.</article-title>
            <source>Cancer</source>
            <year>1977</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>855</fpage>
            <page-range>855-64</page-range>
            <pub-id pub-id-type="pmid">890666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <collab>International CLL-IPI working group</collab>
            <article-title>An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>779</fpage>
            <page-range>779-790</page-range>
            <pub-id pub-id-type="pmid">27185642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoechstetter</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>B&#x000fc;hler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robrecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eckart</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vehling-Kaiser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hurtz</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hopfinger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fuss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abenhardt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Blau</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Freier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goebeler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wendtner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Herling</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Starck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bentz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emmerich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.</article-title>
            <source>Leukemia</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>1038</fpage>
            <page-range>1038-1051</page-range>
            <pub-id pub-id-type="pmid">32042081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morabito</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tripepi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Del Poeta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mauro</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Reda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sportoletti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Laurenti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coscia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herishanu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Varettoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murru</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chiarenza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Visentin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Condoluci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pietrasanta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Loseto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Consoli</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Scortechini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Zucchetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vigna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Mendicino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Botta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caracciolo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cassin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>D'Arrigo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Galimberti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rago</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Angeletti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Biagi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Del Giudice</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bomben</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Neri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fronza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cutrona</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Di Raimondo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cuneo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Polliack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trentin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fo&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferrarini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gattei</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.</article-title>
            <source>Am J Hematol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>96</volume>
            <issue>5</issue>
            <fpage>E168</fpage>
            <page-range>E168-E171</page-range>
            <pub-id pub-id-type="pmid">33580969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayes</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.</article-title>
            <source>J Clin Oncol</source>
            <year>2021</year>
            <month>Jan</month>
            <day>20</day>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-248</page-range>
            <pub-id pub-id-type="pmid">33326253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tausch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Robrecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dolnik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bloehdorn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Al-Sawaf</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ritgen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kreuzer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schary</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bullinger</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lur&#x000e0;</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kneba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.</article-title>
            <source>Blood</source>
            <year>2020</year>
            <month>Jun</month>
            <day>25</day>
            <volume>135</volume>
            <issue>26</issue>
            <fpage>2402</fpage>
            <page-range>2402-2412</page-range>
            <pub-id pub-id-type="pmid">32206772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamblin</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gardiner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oscier</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>FK</given-names>
              </name>
            </person-group>
            <article-title>Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>1999</year>
            <month>Sep</month>
            <day>15</day>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>1848</fpage>
            <page-range>1848-54</page-range>
            <pub-id pub-id-type="pmid">10477713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damle</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Wasil</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fais</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ghiotto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Budman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dittmar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kolitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lichtman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vinciguerra</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Ferrarini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiorazzi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>1999</year>
            <month>Sep</month>
            <day>15</day>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>1840</fpage>
            <page-range>1840-7</page-range>
            <pub-id pub-id-type="pmid">10477712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pflug</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shanafelt</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Elter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Malchau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Eckart</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hopfinger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wendtner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Jul</month>
            <day>03</day>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-62</page-range>
            <pub-id pub-id-type="pmid">24797299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tausch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Close</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dolnik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bloehdorn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chyla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bullinger</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Venetoclax resistance and acquired <italic>BCL2</italic> mutations in chronic lymphocytic leukemia.</article-title>
            <source>Haematologica</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>104</volume>
            <issue>9</issue>
            <fpage>e434</fpage>
            <page-range>e434-e437</page-range>
            <pub-id pub-id-type="pmid">31004028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Orwick</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Doong</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lozanski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lozanski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Misra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ngankeu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozer</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Sampath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thangavadivel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Woyach</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Blachly</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.</article-title>
            <source>Blood</source>
            <year>2020</year>
            <month>Jun</month>
            <day>11</day>
            <volume>135</volume>
            <issue>24</issue>
            <fpage>2192</fpage>
            <page-range>2192-2195</page-range>
            <pub-id pub-id-type="pmid">32232486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blombery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Birkinshaw</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>McBean</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thijssen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Westerman</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Czabotar</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>DCS</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.</article-title>
            <source>Blood</source>
            <year>2020</year>
            <month>Mar</month>
            <day>05</day>
            <volume>135</volume>
            <issue>10</issue>
            <fpage>773</fpage>
            <page-range>773-777</page-range>
            <pub-id pub-id-type="pmid">31951646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Faderl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferrajoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garcia-Manero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Koller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ravandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Jun</month>
            <day>01</day>
            <volume>109</volume>
            <issue>11</issue>
            <fpage>4679</fpage>
            <page-range>4679-85</page-range>
            <pub-id pub-id-type="pmid">17299097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molica</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alberti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia.</article-title>
            <source>Cancer</source>
            <year>1987</year>
            <month>Dec</month>
            <day>01</day>
            <volume>60</volume>
            <issue>11</issue>
            <fpage>2712</fpage>
            <page-range>2712-6</page-range>
            <pub-id pub-id-type="pmid">3677006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patterson</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hadley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herbrecht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kontoyiannis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Marr</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Steinbach</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wingard</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Aug</month>
            <day>15</day>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>e1</fpage>
            <page-range>e1-e60</page-range>
            <pub-id pub-id-type="pmid">27365388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>770</fpage>
            <page-range>770-82, table of contents</page-range>
            <pub-id pub-id-type="pmid">15489347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Helweg-Larsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tsolaki</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wakefield</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping.</article-title>
            <source>QJM</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>91</volume>
            <issue>12</issue>
            <fpage>813</fpage>
            <page-range>813-20</page-range>
            <pub-id pub-id-type="pmid">10024946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Issa</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Infectious complications of antilymphocyte therapies in solid organ transplantation.</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>Mar</month>
            <day>15</day>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>772</fpage>
            <page-range>772-86</page-range>
            <pub-id pub-id-type="pmid">19207081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000fc;hrsen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Augener</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zwingers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brittinger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases.</article-title>
            <source>Br J Haematol</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-9</page-range>
            <pub-id pub-id-type="pmid">3499930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mauro</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Foa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cerretti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giannarelli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coluzzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mandelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Girelli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.</article-title>
            <source>Blood</source>
            <year>2000</year>
            <month>May</month>
            <day>01</day>
            <volume>95</volume>
            <issue>9</issue>
            <fpage>2786</fpage>
            <page-range>2786-92</page-range>
            <pub-id pub-id-type="pmid">10779422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diehl</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Ketchum</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.</article-title>
            <source>Semin Oncol</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-97</page-range>
            <pub-id pub-id-type="pmid">9482530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Visco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laura Evangelista</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stasi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zanotti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giaretta</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ambrosetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madeo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pizzolo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Feb</month>
            <day>01</day>
            <volume>111</volume>
            <issue>3</issue>
            <fpage>1110</fpage>
            <page-range>1110-6</page-range>
            <pub-id pub-id-type="pmid">17986663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mato</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Strelec</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ganetsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nasta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Svoboda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nabhan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Feb</month>
            <day>25</day>
            <volume>127</volume>
            <issue>8</issue>
            <fpage>1064</fpage>
            <page-range>1064-7</page-range>
            <pub-id pub-id-type="pmid">26702066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Slager</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Shanafelt</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study.</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Mar</month>
            <day>01</day>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>930</fpage>
            <page-range>930-7</page-range>
            <pub-id pub-id-type="pmid">23341508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Dali</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hleuhel</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>da Cunha-Bang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brieghel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poulsen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Clasen-Linde</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bentzen</surname>
                <given-names>HHN</given-names>
              </name>
              <name>
                <surname>Frederiksen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Enggaard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Helleberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clausen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frederiksen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Niemann</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>1435</fpage>
            <page-range>1435-1444</page-range>
            <pub-id pub-id-type="pmid">32031030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131137.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsimberidou</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Richter syndrome: biology, incidence, and therapeutic strategies.</article-title>
            <source>Cancer</source>
            <year>2005</year>
            <month>Jan</month>
            <day>15</day>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>216</fpage>
            <page-range>216-28</page-range>
            <pub-id pub-id-type="pmid">15578683</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
